MA35356B1 - Dérivés de 2-amino-4-(pyridine-2-yl)-5,6-dihydro-4h-1,3-oxazine, et leur utilisation comme inhibiteurs de bace1 et bace2 - Google Patents

Dérivés de 2-amino-4-(pyridine-2-yl)-5,6-dihydro-4h-1,3-oxazine, et leur utilisation comme inhibiteurs de bace1 et bace2

Info

Publication number
MA35356B1
MA35356B1 MA36766A MA36766A MA35356B1 MA 35356 B1 MA35356 B1 MA 35356B1 MA 36766 A MA36766 A MA 36766A MA 36766 A MA36766 A MA 36766A MA 35356 B1 MA35356 B1 MA 35356B1
Authority
MA
Morocco
Prior art keywords
bace2
bace1
oxazine
pyridin
dihydro
Prior art date
Application number
MA36766A
Other languages
English (en)
Inventor
Rainer Martin Lueoend
Rainer Machauer
Heinrich Rueeger
Siem Jacob Veenstra
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47018309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35356(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA35356B1 publication Critical patent/MA35356B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne de nouveaux dérivés d'oxazine représentés par la formule (i) et certains de leurs sels pharmaceutiquement admis, formule dans laquelle les variables sont telles que définies dans la spécification. L'invention concerne également certaines de leurs compositions pharmaceutiques, de leurs combinaisons, et leur utilisation comme médicaments, en particulier pour le traitement de la maladie d'alzheimer ou du diabète par inhibition de bace1 ou bace2.
MA36766A 2011-08-25 2014-02-20 Dérivés de 2-amino-4-(pyridine-2-yl)-5,6-dihydro-4h-1,3-oxazine, et leur utilisation comme inhibiteurs de bace1 et bace2 MA35356B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161527172P 2011-08-25 2011-08-25
US201261665395P 2012-06-28 2012-06-28
PCT/IB2012/054269 WO2013027188A1 (fr) 2011-08-25 2012-08-23 Dérivés de 2-amino-4-(pyridine-2-yl)-5,6-dihydro-4h-1,3-oxazine, et leur utilisation comme inhibiteurs de bace1 et bace2

Publications (1)

Publication Number Publication Date
MA35356B1 true MA35356B1 (fr) 2014-08-01

Family

ID=47018309

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36766A MA35356B1 (fr) 2011-08-25 2014-02-20 Dérivés de 2-amino-4-(pyridine-2-yl)-5,6-dihydro-4h-1,3-oxazine, et leur utilisation comme inhibiteurs de bace1 et bace2

Country Status (28)

Country Link
US (2) US9163011B2 (fr)
EP (2) EP3023423B1 (fr)
JP (1) JP5816369B2 (fr)
KR (1) KR101601571B1 (fr)
CN (1) CN103906748B (fr)
AP (1) AP2014007507A0 (fr)
AR (1) AR087668A1 (fr)
AU (1) AU2012298177B2 (fr)
BR (1) BR112014004131A2 (fr)
CA (1) CA2845093A1 (fr)
CL (1) CL2014000458A1 (fr)
CO (1) CO6890097A2 (fr)
CR (1) CR20140084A (fr)
EA (1) EA024580B1 (fr)
ES (2) ES2638832T3 (fr)
GT (1) GT201400031A (fr)
IL (1) IL230975A0 (fr)
MA (1) MA35356B1 (fr)
MX (1) MX339303B (fr)
PE (1) PE20141540A1 (fr)
PH (1) PH12014500356A1 (fr)
PL (1) PL2748162T3 (fr)
SG (1) SG2014012108A (fr)
TN (1) TN2014000062A1 (fr)
TW (1) TW201313706A (fr)
UY (1) UY34278A (fr)
WO (1) WO2013027188A1 (fr)
ZA (1) ZA201401139B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101324426B1 (ko) 2008-06-13 2013-10-31 시오노기세야쿠 가부시키가이샤 β 세크레타제 저해 작용을 갖는 황 함유 복소환 유도체
MX2012006491A (es) 2009-12-11 2012-07-03 Shionogi & Co Derivados de oxazina.
MY162413A (en) 2011-01-13 2017-06-15 Novartis Ag Novel heterocyclic derivatives and their use in the treatment of neurological disorders
EP2912035A4 (fr) 2012-10-24 2016-06-15 Shionogi & Co Dérivés de dihydrooxazine ou d'oxazépine ayant une activité inhibitrice de bace1
WO2014134341A1 (fr) * 2013-03-01 2014-09-04 Amgen Inc. Composés perfluorés 5,6-dihydro-4h-1,3-oxazine-2-amine substitués en tant qu'inhibiteurs de la bêta-sécrétase et procédés d'utilisation correspondants
MX374512B (es) 2013-03-08 2025-03-06 Amgen Inc Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y métodos de uso.
AU2014253275B2 (en) * 2013-04-11 2018-10-18 F. Hoffmann-La Roche Ag BACE1 inhibitors
JO3318B1 (ar) 2013-06-18 2019-03-13 Lilly Co Eli مثبطات bace
KR20160115936A (ko) 2014-02-19 2016-10-06 하. 룬드벡 아크티에셀스카브 알츠하이머병의 치료를 위한 bace1 저해제로서의 2-아미노-3,5,5-트리플루오로-3,4,5,6-테트라하이드로피리딘
TW201623295A (zh) 2014-04-11 2016-07-01 塩野義製藥股份有限公司 具有ｂａｃｅ１抑制活性之二氫噻及二氫衍生物
CN106795147B (zh) 2014-08-08 2020-09-22 美国安进公司 作为β-分泌酶抑制剂的环丙基稠合噻嗪-2-胺化合物和使用方法
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
JP6887952B2 (ja) 2015-02-25 2021-06-16 プリレニア ニューロセラピューティクス リミテッド 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
TW201717948A (zh) 2015-08-10 2017-06-01 Ｈ 朗德貝克公司 包括給予２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶的聯合治療
EP3334720A1 (fr) 2015-08-12 2018-06-20 H. Lundbeck A/S 2-amino-3-fluoro-3-(fluorométhyl)-6-méthyl-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
EP3423450B1 (fr) * 2016-03-01 2019-11-27 H. Hoffnabb-La Roche Ag Inhibiteurs de bace1
AU2017376441B2 (en) * 2016-12-15 2021-10-14 Amgen Inc. Oxazine derivatives as beta-secretase inhibitors and methods of use
CA3047290A1 (fr) 2016-12-15 2018-06-21 Amgen Inc. Derives de dioxyde de 1,4-thiazine et de dioxyde de 1,2,4-thiadiazine en tant qu'inhibiteurs de beta-secretase et procedes d'utilisation
MX394391B (es) 2016-12-15 2025-03-24 Amgen Inc Derivados de tiazina y oxazina biciclicos como inhibidores de beta-secretasa y metodos de uso.
EP3555085B1 (fr) 2016-12-15 2020-12-02 Amgen Inc. Derivés thiazine fusionnés à un cyclopropyle utilisés en tant qu'inhibiteurs de la bêta-sécrétase et procédés d'utilisation
CA3047288A1 (fr) 2016-12-15 2018-06-21 Amgen Inc. Derives de thiazine en tant qu'inhibiteurs de beta-secretase et procedes d'utilisation
AU2019258575A1 (en) 2018-04-27 2020-10-29 Shionogi & Co., Ltd. Tetrahydropyranooxazine derivatives having selective BACE1 inhibitory activity
CN109725092A (zh) * 2019-03-19 2019-05-07 北京和合医学诊断技术股份有限公司 检测血液中齐拉西酮含量的液相色谱分析方法
US12042492B2 (en) 2020-10-09 2024-07-23 Texas Tech University System BACE1 inhibitory ligand molecules against amyloid beta-induced synaptic and mitochondrial toxicities
CN113173852B (zh) * 2021-04-26 2022-07-12 深圳市华先医药科技有限公司 二氟丙二酸酯类化合物的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6911868A (fr) 1968-08-31 1970-03-03
WO2003006426A1 (fr) * 2001-07-13 2003-01-23 Axxima Pharmaceuticals Ag Guanylhydrazones aromatiques utilises comme composes efficaces contre les maladies nerveuses
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
CA2525764C (fr) 2003-05-20 2012-07-17 Novartis Ag Heterocycles d'azote n-acyle utilises comme ligands des recepteurs actives par les proliferateurs de peroxysomes
CA2628074C (fr) 2005-10-25 2014-01-14 Shionogi & Co., Ltd. Derive aminodihydrothiazine
US8653067B2 (en) 2007-04-24 2014-02-18 Shionogi & Co., Ltd. Pharmaceutical composition for treating Alzheimer's disease
JP5383484B2 (ja) * 2007-04-24 2014-01-08 塩野義製薬株式会社 環式基で置換されたアミノジヒドロチアジン誘導体
CN102186841A (zh) * 2008-10-22 2011-09-14 盐野义制药株式会社 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物
WO2010063718A1 (fr) 2008-12-02 2010-06-10 ETH Zürich Essai de criblage pour des agents thérapeutiques contre une maladie métabolique
US8461160B2 (en) * 2009-05-08 2013-06-11 Hoffmann-La Roche, Inc. Dihydropyrimidinones
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
US7964594B1 (en) 2009-12-10 2011-06-21 Hoffmann-La Roche Inc. Amino oxazine derivatives
MX2012006491A (es) 2009-12-11 2012-07-03 Shionogi & Co Derivados de oxazina.
UA103272C2 (uk) * 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
JP2014505689A (ja) 2011-01-13 2014-03-06 ノバルティス アーゲー 代謝障害の処置用ｂａｃｅ−２阻害剤
ES2624288T3 (es) 2011-01-21 2017-07-13 Eisai R&D Management Co., Ltd. Métodos y compuestos útiles en la síntesis de derivados de aminodihidrotiazina condensados
US8404680B2 (en) 2011-02-08 2013-03-26 Hoffmann-La Roche Inc. N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors
US8754075B2 (en) 2011-04-11 2014-06-17 Hoffmann-La Roche Inc. 1,3-oxazines as BACE1 and/or BACE2 inhibitors
US8883779B2 (en) 2011-04-26 2014-11-11 Shinogi & Co., Ltd. Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them
US8785436B2 (en) 2011-05-16 2014-07-22 Hoffmann-La Roche Inc. 1,3-oxazines as BACE 1 and/or BACE2 inhibitors
CA2837797A1 (fr) 2011-06-07 2012-12-13 F. Hoffmann-La Roche Ag [1,3]oxazines
CN103717592A (zh) 2011-06-07 2014-04-09 霍夫曼-拉罗奇有限公司 作为bace1和/或bace2抑制剂的卤代-烷基-1,3噁嗪类

Also Published As

Publication number Publication date
AU2012298177B2 (en) 2015-10-29
PE20141540A1 (es) 2014-10-31
US20130172331A1 (en) 2013-07-04
ZA201401139B (en) 2014-12-23
BR112014004131A2 (pt) 2017-06-13
EA024580B1 (ru) 2016-09-30
ES2565229T3 (es) 2016-04-01
US9163011B2 (en) 2015-10-20
CL2014000458A1 (es) 2014-09-05
WO2013027188A1 (fr) 2013-02-28
NZ621093A (en) 2015-05-29
KR101601571B1 (ko) 2016-03-08
IL230975A0 (en) 2014-03-31
EP3023423B1 (fr) 2017-05-31
PH12014500356A1 (en) 2014-04-07
UY34278A (es) 2013-04-05
ES2638832T3 (es) 2017-10-24
TW201313706A (zh) 2013-04-01
MX339303B (es) 2016-05-19
CA2845093A1 (fr) 2013-02-28
CO6890097A2 (es) 2014-03-10
HK1195903A1 (en) 2014-11-28
AP2014007507A0 (en) 2014-03-31
CN103906748B (zh) 2017-06-16
PL2748162T3 (pl) 2016-06-30
EP2748162B1 (fr) 2015-12-16
CR20140084A (es) 2014-05-02
JP5816369B2 (ja) 2015-11-18
EA201490491A1 (ru) 2014-06-30
SG2014012108A (en) 2014-05-29
EP2748162A1 (fr) 2014-07-02
JP2014524463A (ja) 2014-09-22
TN2014000062A1 (en) 2015-07-01
GT201400031A (es) 2015-02-19
KR20140054313A (ko) 2014-05-08
AU2012298177A1 (en) 2014-03-06
CN103906748A (zh) 2014-07-02
EP3023423A1 (fr) 2016-05-25
AR087668A1 (es) 2014-04-09
US20150150877A1 (en) 2015-06-04
MX2014002230A (es) 2014-04-25

Similar Documents

Publication Publication Date Title
MA35356B1 (fr) Dérivés de 2-amino-4-(pyridine-2-yl)-5,6-dihydro-4h-1,3-oxazine, et leur utilisation comme inhibiteurs de bace1 et bace2
MA34898B1 (fr) Nouveaux dérivés hétérocycliques et leur utilisation dans le traitement de troubles neurologiques
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA35246B1 (fr) 1,3-oxazines en tant qu'inhibiteurs de bace1 et/ou de bace2
EA201490774A1 (ru) Новые производные оксазина и их применение при лечении заболевания
MA35193B1 (fr) Halogeno-alkyl-1,3 oxazines en tant qu'inhibiteurs de bace1 et/ou bace2
EA201391468A1 (ru) 1,3-оксазины в качестве ингибиторов bace1 и/или bace2
EA200870423A1 (ru) Производные триазолпиразинов, применимые в качестве противораковых агентов
BR112013031510A2 (pt) [1,3]oxazinas
UA103272C2 (uk) 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
MA42295B1 (fr) Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation
MA35191B1 (fr) Spiro-[1,3]-oxazines et spiro-[1,4]-oxazepines en tant qu'inhibiteurs de baec1 et/ou bace2
MA35748B1 (fr) Fluorométhyl-5,6-dihydro-4h-[1,3]oxazines
IN2012DN00766A (fr)
EA201001508A1 (ru) Мостиковые гетероциклические соединения в качестве ингибиторов интегразы вич
SE0402735D0 (sv) Novel compounds
MX2013007558A (es) 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2).
MX2013007957A (es) 1,4-oxazinas como inhibidores de los genes de enzima de segmentacion de la proteina precursora amiloide del sitio beta 1 y/o (bace1 y/o bace2).
BR112014006763A2 (pt) n-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexa-hidro-ciclopenta[e][1,3]oxazin-4-il)-fenil)-amidas como inibidores de bace1
EA200870577A1 (ru) Конденсированные трициклические сульфонамидные ингибиторы гамма-секретазы
MA38315A1 (fr) Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales
MA38287A1 (fr) Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer
MA33760B1 (fr) Dérivés spirolactames et leurs utilisations
MA34008B1 (fr) Composes en tant qu'antagonistes de la bradykinine b1
MA37691B1 (fr) 5-amino[1,4]thiazines comme inhibiteurs de bace1